What Soligenix’s Q1 update reveals about biotech risk after a failed confirmatory trial
HyBryte’s setback leaves Soligenix with cash, orphan assets, and a harder question. Can SGX945 reset the rare disease story?
Pharma & Biotech
Pharma & Biotech
How Soligenix is trying to turn tolerability and treatment logistics into a differentiated regulatory and commercial story
Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.
Pharma & Biotech
Asieris Pharmaceuticals launches CEVIRA in China, challenging surgical dominance in CIN2 therapy
China approves CEVIRA, the first non-invasive therapy for CIN2 cervical precancer. Discover what this means for treatment pathways and global adoption.
Pharma & Biotech
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
Pharma & Biotech
What Biofrontera’s Phase 3 results mean for non-facial actinic keratosis treatment strategies
Biofrontera reports positive Phase 3 Ameluz data outside the face and scalp. Find out how this could change actinic keratosis treatment.